Cheaper keytruda copycat tested in lung cancer patients
NCT ID NCT07162883
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests QL2107, a biosimilar (copy) of the cancer drug Keytruda, in 122 adults with non-small cell lung cancer that has been surgically removed. The goal is to see if the body processes QL2107 the same way as Keytruda when given as an extra treatment after surgery and chemotherapy. If successful, it could lead to a lower-cost option for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL2107 (a biosimilar of pembrolizumab, the drug in Keytruda)
What this could lead to
If QL2107 works as well as Keytruda, it could offer a more affordable treatment option for lung cancer patients after surgery.
What could go wrong
This is an early-stage comparison study focused on drug levels, not yet on actual cancer outcomes. The biosimilar may not prove equally effective or safe in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.